Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX in hemodialysis patients with gastrointestinal cancer
jRCTs051190120Active, not recruiting
- Sponsor
- Grant-in-Aid for Scientific Research
- Start
- Mar 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of oxaliplatin, fluorouracil and folinic acid in esophageal cancer, gastric cancer (GC), small bowel cancer and 1 more, sponsored by Grant-in-Aid for Scientific Research. Primary endpoints: Recommended starting dose and Completion rate of chemotherapy. Started Mar 2020; status: active, not recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
esophageal cancergastric cancer (GC)small bowel cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs051190120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190120.